Pulmonary Edema Therapeutics Market 2024-2028: Size and Adverse effects of available therapeutics; growth driven by the Type, Some of key Companies Positioned Strategically

The pulmonary edema therapeutics market size by Type (Cardiogenic pulmonary edema and Non-cardiogenic pulmonary edema) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 365.5 million. The market is expected to grow at a CAGR of   3.27% between 2024 and 2028.

• The pulmonary edema therapeutics market experiences significant demand due to the increasing prevalence of underlying conditions such as congestive heart failure and kidney disease. However, the market growth is challenged by the adverse effects associated with these treatments. Mild adverse events include headache, fever, chills, nausea, and vomiting. Specifically, LASIX, a commonly used diuretic, carries side effects such as stomach cramping, vertigo, dizziness, blurred vision, itching, and rashes. The US Food and Drug Administration (FDA) has issued a black box warning for LASIX due to its potential for causing dehydration, which can lead to serious adverse effects including electrolyte imbalances and kidney damage. These risks may hinder market expansion during the forecast period.
• The Pulmonary Edema Therapeutics Market represents a significant business opportunity for pharmaceutical companies, driven by the increasing prevalence of heart failure and respiratory diseases. Key players in this market focus on developing innovative treatments to address the unmet medical needs of patients, utilizing advanced technologies and therapeutic approaches. Market growth is expected due to the rising demand for effective and safe treatments, as well as regulatory support for new product approvals.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• AbbVie Inc.
• ADVANZ PHARMA
• Apotex Inc.
• Bausch Health Companies Inc.
• Baxter International Inc.
• CHIESI Farmaceutici SpA
• CMP Pharma Inc.
• Emcure Pharmaceuticals Ltd.
• Epic Pharma LLC
• Fresenius Kabi AG
• Hikma Pharmaceuticals Plc
• Johnson and Johnson Services Inc.
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Shanghai Fosun Pharmaceutical Group Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Validus Pharmaceuticals LLC
• Viatris Inc.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/